Teva intros generic Atelvia tabs

NORTH WALES, Penn. — Teva Pharmaceuticals on Tuesday announced the introduction of risedronate sodium delayed-release tablets, the equivalent to Atelvia delayed-release tablets. According to the company, the drug is used to treat postmenopausal osteoporosis.

 

“Our customers count on Teva for a continuous supply of new generic products,” said Maureen Cavanaugh, SVP, U.S. generics sales and marketing. “With the launch of Risedronate Sodium Delayed-Release Tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”